Advertisement

Heart in Hyperthyroidism

  • Bernadette Biondi
  • George J. Kahaly
Chapter

Abstract

Hyperthyroidism is a common endocrine disorder that produces important clinical consequences on the cardiovascular system. In overt hyperthyroidism the increase in left ventricular performance is predominantly sustained by an increased preload with enhanced left ventricular diastolic function and reduced systemic vascular resistance. The pattern of cardiovascular abnormalities is similar in subclinical and overt hypothyroidism, suggesting that a lesser degree of thyroid hormone deficiency may also affect the cardiovascular system. Untreated overt and subclinical hypothyroidism can lead to an increased risk of coronary heart disease (CHD), heart failure (HF), and cardiovascular mortality.

Prompt and effective recognition of cardiac manifestations of hyperthyroidism is crucial as cardiovascular complications account for most of the deaths in hyperthyroid patients. Graves’ disease should be considered in patients with pulmonary hypertension, dilated cardiomyopathy, and peripartum cardiomyopathy of unknown etiology.

Doppler echocardiography is a useful technique to assess cardiovascular complications in hyperthyroid patients with cardiac symptoms. Its use is justified in symptomatic patients as it allows assessment of potential cardiovascular involvement.

Correction of overt and subclinical hyperthyroidism should be the first step in improving the prognosis of hyperthyroid patients with cardiovascular complications.

The etiology of hyperthyroidism must be established to enable correct treatment of the disease and of the related cardiovascular complications.

Keywords

Subclinical hyperthyroidism Overt hyperthyroidism Cardiovascular risk Management Antithyroid drugs Radioactive iodine Surgery 

References

  1. 1.
    Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26:704–28.CrossRefGoogle Scholar
  2. 2.
    Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–9.CrossRefGoogle Scholar
  3. 3.
    Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50.CrossRefGoogle Scholar
  4. 4.
    Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725–35.CrossRefGoogle Scholar
  5. 5.
    Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol. 2008;29:211–8.CrossRefGoogle Scholar
  6. 6.
    Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333(23):1522–7.CrossRefGoogle Scholar
  7. 7.
    Palmieri EA, Fazio S, Palmieri V, Lombardi G, Biondi B. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol. 2004;150:757–62.CrossRefGoogle Scholar
  8. 8.
    Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968–74.CrossRefGoogle Scholar
  9. 9.
    Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, Fazio S, Saccá L. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001;104:3076–80.CrossRefGoogle Scholar
  10. 10.
    Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab. 1991;73(1):146–50.CrossRefGoogle Scholar
  11. 11.
    Kahaly GJ, Hellermann J, Mohr-Kahaly S, Treese N. Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism. Chest. 1996;109:57–61.CrossRefGoogle Scholar
  12. 12.
    Kahaly GJ, Nieswandt J, Wagner S, Schlegel J, Mohr-Kahaly S, Hommel G. Ineffective cardiorespiratory function in hyperthyroidism. J Clin Endocrinol Metab. 1998;83:4075–8.PubMedGoogle Scholar
  13. 13.
    Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–43.CrossRefGoogle Scholar
  14. 14.
    Ojamaa K. Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. Vasc Pharmacol. 2010;52:113–9.CrossRefGoogle Scholar
  15. 15.
    Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccá L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4702–5.Google Scholar
  16. 16.
    Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88:1672–7.CrossRefGoogle Scholar
  17. 17.
    Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131.CrossRefGoogle Scholar
  18. 18.
    Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–54.CrossRefGoogle Scholar
  19. 19.
    Hammond HK, White FC, Buxton IL, Saltzstein P, Brunton LL, Longhurst JC. Increased myocardial ß-receptors and adrenergic responses in hyperthyroid pigs. Am J Phys. 1987;252:H283–90.Google Scholar
  20. 20.
    Hoit BD, Khoury SF, Shao Y, Gabel M, Ligget SB, Walsh RA. Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation. 1997;96:592–8.CrossRefGoogle Scholar
  21. 21.
    Ojamaa K, Klein I, Sabet A, Steinberg SF. Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism. 2000;49:275–9.CrossRefGoogle Scholar
  22. 22.
    Carvalho-Bianco SD, Kim BW, Zhang JX, Harney JW, Ribeiro RS, Gereben B, Bianco AC, Mende U, Larsen PR. Chronic cardiac-specific thyrotoxicosis increases myocardial beta-adrenergic responsiveness. Mol Endocrinol. 2004;18(7):1840–9.CrossRefGoogle Scholar
  23. 23.
    Bachman ES, Hampton TG, Dhillon H, Amende I, Wang J, Morgan JP, Hollenberg AN. The metabolic and cardiovascular effects of hyperthyroidism are largely independent of beta-adrenergic stimulation. Endocrinology. 2004;145(6):2767–74.CrossRefGoogle Scholar
  24. 24.
    Brodde OE. ß1- and ß2-adrenoreceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203–42.PubMedGoogle Scholar
  25. 25.
    Bahouth SW. Thyroid hormones transcriptionally regulate the ß1-adrenergic receptor gene in cultured ventricular myocytes. J Biol Chem. 1991;266:15863–9.PubMedGoogle Scholar
  26. 26.
    Bahouth SW, Cui X, Beauchamp MJ, Park EA. Thyroid hormone induces β1 –adrenergic receptor gene transcription through a direct repeat separated by five nucleotides. J Mol Cell Cardiol. 1997;29:3223–37.CrossRefGoogle Scholar
  27. 27.
    Biondi B. Heart failure and thyroid dysfunction. Eur J Endocrinol. 2012;167:609–18.CrossRefGoogle Scholar
  28. 28.
    Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH. J subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. Clin Endocrinol Metab. 2014;99(7):2372–282.CrossRefGoogle Scholar
  29. 29.
    DeGroot WJ, Leonard JJ. Hyperthyroidism as a high cardiac output state. Am Heart J. 1970;79:265–75.CrossRefGoogle Scholar
  30. 30.
    Cruz FE, Cheriex EC, Smeets JL, Atie J, Peres AK, Penn OC, Brugada P, Wellens HJ. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Card. 1990;16:739–44.CrossRefGoogle Scholar
  31. 31.
    Soh MC, Croxson M. Fatal thyrotoxic cardiomyopathy in a young man. BMJ. 2008;28:337–531.Google Scholar
  32. 32.
    Yue WS, Chong BH, Zhang XH, Liao SY, Jim MH, Kung AW, Tse HF, Siu CW. Hyperthyroidism-induced left ventricular diastolic dysfunction: implication inhyperthyroidism-related heart failure. Clin Endocrinol. 2011;74:636–43.CrossRefGoogle Scholar
  33. 33.
    Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93:483–7.CrossRefGoogle Scholar
  34. 34.
    Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WPJ, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, RGJ W, Vittinghoff E, Aujesky D, Rodondi N. Thyroid studies collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from six prospective cohorts. Circulation. 2012;126:1040–9.CrossRefGoogle Scholar
  35. 35.
    Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Saccà L. Controls of adrenergic contracticity. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78(5):1028–33.PubMedGoogle Scholar
  36. 36.
    Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med. 2004;164:1675–8.CrossRefGoogle Scholar
  37. 37.
    Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, Thyroid studies collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799–809.CrossRefGoogle Scholar
  38. 38.
    Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005;36:2302–10.CrossRefGoogle Scholar
  39. 39.
    Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. J Thromb Haemost. 2010;8:2176–81.CrossRefGoogle Scholar
  40. 40.
    Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41:961–6.CrossRefGoogle Scholar
  41. 41.
    Lin HC, Yang, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. J Thromb Haemost. 2010;8:2176–81.CrossRefGoogle Scholar
  42. 42.
    Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol. 2014;29:791–800.CrossRefGoogle Scholar
  43. 43.
    Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension:a prospective echocardiographic study. J Clin Endocrinol Metab. 2007;2:1736–42.CrossRefGoogle Scholar
  44. 44.
    Li JH, Safford RE, Aduen JF, Heckman MG, Crook JE, Burger CD. Pulmonary hypertension and thyroid disease. Chest. 2007;132:793–7.CrossRefGoogle Scholar
  45. 45.
    Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev. 2004;12:299–305.CrossRefGoogle Scholar
  46. 46.
    Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med. 2007;22:148–50.CrossRefGoogle Scholar
  47. 47.
    Ma RC, Cheng AY, So WY, Hui DS, Tong PC, Chow CC. Thyrotoxicosis and pulmonary hypertension. Am J Med. 2005;118(8):927–8.CrossRefGoogle Scholar
  48. 48.
    Cohen J, Shattner A. Right heart failure and hyperthyroidism: a neglected presentation. Am J Med. 2003;115:76–7.CrossRefGoogle Scholar
  49. 49.
    Mercé J, Ferrás S, Oltra C, Sanz E, Vendrell J, Simón I, Camprubí M, Bardají A, Ridao C. Ary hypertension. Am J Med. 2005;118(2):126–31.CrossRefGoogle Scholar
  50. 50.
    Drvota V, Janson A, Norman C, Sylvén C, Häggblad J, Brönnegård M, Marcus C. Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem Biophys Res Commun. 1995;211:426–31.CrossRefGoogle Scholar
  51. 51.
    Shirani J, Barron MM, Pierre-Louis ML, Roberts WC. Congestive heart failure, dilated cardiac ventricles, and sudden death in hyperthyroidism. Am J Cardiol. 1993;72:365–8.CrossRefGoogle Scholar
  52. 51.
    Fatourechi V, Edwards WD. Graves’ disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients. Thyroid. 2000;10:601–5.CrossRefGoogle Scholar
  53. 52.
    Boccaladro C, Boccalandro F, Orlander P, Wei CF. Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the literature. Endocr Pract. 2003;9:140–6.CrossRefGoogle Scholar
  54. 53.
    Londhey VA, Kamble US, Limaye CS, Pednekar SJ, Kini SH, Borges NE. Irreversible dilated cardiomyopathy due to thyrotoxicosis. J Assoc Physicians India. 2006;54:575–6.PubMedGoogle Scholar
  55. 54.
    Ebisawa K, Ikeda U, Murata M, Sekiguchi H, Nagai R, Yazaki Y, Shimada K. Irreversible cardiomyopathy due to thyrotoxicosis. Cardiology. 1994;84:274–7.CrossRefGoogle Scholar
  56. 55.
    Al-Ghamdi AS, Aljohani N. Graves’ thyrotoxicosis-induced reversible cardiomyopathy: a case report. Clin Med Insights Case Rep. 2013;27:47–50.Google Scholar
  57. 56.
    Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol. 2012;167:295–9.CrossRefGoogle Scholar
  58. 57.
    Anderson JL, Halperin JL, Albert NM. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations) a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935–44.CrossRefGoogle Scholar
  59. 58.
    Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, IR cD, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.CrossRefGoogle Scholar
  60. 59.
    Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;3:149–1463.CrossRefGoogle Scholar
  61. 60.
    Osman F, Franklyn J, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy a matched case–control study. J Am Coll Cardiol. 2007;49:71–81.CrossRefGoogle Scholar
  62. 61.
    Nakazawa K, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982;72:903–6.CrossRefGoogle Scholar
  63. 62.
    Shimizu TKS, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12:489–93.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical Medicine and SurgeryUniversity of Naples Federico IINaplesItaly
  2. 2.Department of Medicine IJohannes Gutenberg University Medical CenterMainzGermany

Personalised recommendations